Ascelia Pharma today has received a Complete Response Letter (CRL) from the FDA, the scheduled PDUFA date for Orviglance, its oral, gadolinium-free liver contrast agent for cancer patients with severe renal impairment.

The FDA stated it cannot approve the application in its present form and has requested additional clinical data and product documentation. Management will request a Type A meeting with the FDA "as soon as possible" to clarify the deficiencies and identify the fastest realistic path to approval.

CEO Magnus Corfitzen said: "We remain confident in Orviglance and are committed to making it available to patients." The letter itself, however, removes the near-term catalyst that anchored our investment case, and the shares now appear to price in a market-implied probability of success (PoS) of roughly 10%, down sharply from a base case of around 39% ahead of the decision.

The central issue for the case going forward is that the CRL, as disclosed, gives almost no detail on severity. "Additional clinical data and product documentation" is a broad category that spans two very different scenarios.

At the mild end, the FDA may be asking for reanalysis of existing SPARKLE data, additional documentation, or CMC/labelling-level clarifications, the kind of request typically resolved through a Class 1 resubmission with a two-month FDA review clock.

At the severe end, the letter could signal that the agency wants a new clinical dataset entirely, which would imply a Class 2 resubmission (six-month review at minimum) and, if a new trial is genuinely required, a multi-year delay well beyond that.

Ascelia has not yet characterized which end of that spectrum applies, and the Type A meeting, not yet scheduled, is the event that should provide the first real clarity.

Until then, the range of reasonable outcomes is unusually wide for a single binary catalyst.

This uncertainty matters directly for the balance sheet. Ascelia has previously guided to a cash runway into 2027, sufficient to cover a standard resubmission cycle built around clarifications, reanalyses, or document-level fixes. It would not comfortably cover the cost and time of designing, running, and reporting a new pivotal trial. Management's statement that it will "assess potential cost saving initiatives" alongside the CRL disclosure is itself a signal that the company is preparing for the possibility of a longer runway need, though it stops short of confirming which scenario it expects. If the FDA's request turns out to require new Phase 3 level evidence, we would expect the company to need additional financing before an eventual resubmission is reviewed, most likely on dilutive terms given the setback to sentiment.

We also looked for a statistical anchor for how often a CRL is eventually followed by approval, to help frame the ~10% implied PoS against some historical base rate, similar to how we use the ~91% Phase III completion benchmark elsewhere in the model.

We were not able to find one that holds up. FDA's own published CRL archive is not usable for this purpose: the "approved" and "unapproved" batches were released separately and selectively. The approved batch was explicitly curated from historical CRLs tied to drugs that were later approved, while the unapproved batch is almost entirely applications from 2024 onward that simply have not had time to resolve either way. Comparing the two gives a misleadingly high or low rate depending on where you cut the data, not a genuine population-level estimate.

In the absence of a reliable external benchmark, the market's roughly 10% implied PoS (base -case), based on the current share price of SEK 0,755, should be read as a judgment call on severity risk under genuine information scarcity, rather than a statistically grounded figure.

Net, the setback is real and removes the clean binary catalyst the case was built around, but it does not yet tell us whether Ascelia is looking at a matter of months or a matter of years. The Type A meeting request, and specifically whether FDA classifies any eventual resubmission as Class 1 or Class 2, is the next concrete data point to watch, alongside any update to the cash runway once the scope of the FDA's requirements is known.

We will await further clarity from the Type A meeting before updating our investment case. The outcome of that meeting is the primary driver for how we should think about the probability of success going forward, given how little is currently known about the severity of the FDA's requested changes. This will naturally affect our valuation, as a lower or higher assessed PoS feeds directly into the model, and the market's roughly 10% implied PoS already reflects that repricing.

What has not changed, in our view, is the underlying commercial opportunity if Orviglance is eventually approved: an addressable market of USD 800m annually, a 25% royalty rate assumption, orphan drug exclusivity, and limited competition. The CRL raises the bar for reaching approval and pushes out the likely timeline, but it does not by itself materially alter what the asset would be worth on the other side of a resubmission and potential approval.

CRL also has a direct bearing on the second major catalyst we have highlighted, a partnership agreement. A signing had already become less likely to occur pre-approval based on recent management commentary, and that now looks considerably more remote. A potential partner has even less incentive to commit capital or agree to terms while the regulatory path is unresolved and the severity of the FDA's concerns is unknown and is likely to wait for at least the Type A meeting outcome, if not full resolution of the CRL, before engaging seriously.

With both of the high-value 2026 catalysts we previously identified now delayed or at greater risk, near-term news flow is likely to be thin, until the Type A meeting provides more direction.

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. Michael Friis 16:12 03/07-2026.